Aligos Therapeutics’ $83.6 Million Public Offering

Latham & Watkins LLP represented Aligos Therapeutics, while Davis Polk advised the representatives of the several underwriters in the offering.

Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced the pricing of its underwritten public offering of 4,400,000 shares of common stock at a public offering price of US$19 per share. In addition, Aligos has granted the underwriters a 30-day option to purchase up to an additional 660,000 shares of common stock at the same terms and conditions. All of the shares of common stock are being offered by Aligos. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Aligos, are expected to be approximately US$83.6 million, excluding any exercise of the underwriters’ option to purchase additional shares.

Aligos is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis. Aligos Therapeutics is headquartered in South San Francisco, California.

Latham & Watkins LLP represented Aligos Therapeutics in the offering with a corporate deal team led by Bay Area partners Mark Roeder (Picture) and John Williams, with associates Theresa Bloom, Christopher Pham, and Natalie Robertson. Advice has also been provided on employee benefits and compensation matters by Bay Are partner Jay Metz and associate Erik Ward; on tax matters by Bay Area partner Kirt Switzer and associate Gregory Conyers; on regulatory matters by Washington, D.C. partner John Manthei, Bay Area counsels Betty Pang and Heather Deixler, and associates Monica Groat in Washington, D.C., Ning Heather Lui in Los Angeles, Kiera Murphy in San Diego, and Lee Staley in Boston; and on data and technology matters by New York partner Alan Tamarelli, Bay Area partner Christopher Hazuka, and Boston associate Seth Appiah-Opoku.

The Davis Polk corporate team advising J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co., acting as representatives of the underwriters, included partner Alan F. Denenberg and associates Beth LeBow and Elsie Cheang. Partner Michael Farber and associate Benjamin Helfgott provided tax advice. Partner David R. Bauer and associate Daniel P. Kearney provided intellectual property advice. Counsel Marcie A. Goldstein provided FINRA advice. Associate Jason Cohen provided 1940 Act advice.

Involved fees earner: David Bauer – Davis Polk & Wardwell; Elsie Cheang – Davis Polk & Wardwell; Jason Cohen – Davis Polk & Wardwell; Alan Denenberg – Davis Polk & Wardwell; Michael Farber – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell; Benjamin Helfgott – Davis Polk & Wardwell; Daniel Kearney – Davis Polk & Wardwell; Beth LeBow – Davis Polk & Wardwell; Seth Appiah-Opoku – Latham & Watkins; Theresa Bloom – Latham & Watkins; Gregory Conyers – Latham & Watkins; Heather Deixler – Latham & Watkins; Monica Groat – Latham & Watkins; Christopher Hazuka – Latham & Watkins; Ning Heather Lui – Latham & Watkins; John Manthei – Latham & Watkins; James Metz – Latham & Watkins; Kiera Murphy – Latham & Watkins; Betty Pang – Latham & Watkins; Christopher Pham – Latham & Watkins; Natalie Robertson – Latham & Watkins; Mark Roeder – Latham & Watkins; Lee Staley – Latham & Watkins; Kirt Switzer – Latham & Watkins; Alan Tamarelli Jr. – Latham & Watkins; Erik Ward – Latham & Watkins; John Williams – Latham & Watkins;

Law Firms: Davis Polk & Wardwell; Latham & Watkins;

Clients: Aligos Therapeutics; J.P. Morgan Securities LLC; Jefferies; Piper Sandler;

Author: Martina Bellini